Mouse Models of Radiosensitivity

Eugenia M Yazlovitskaya1,2*

1Department of Medicine, Division of Nephrology, Vanderbilt University Medical Center, USA
2Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

Ionizing radiation (IR) is a known environmental, medical, and military hazard that can produce dreadful health impairments. At the molecular and cellular level, radiation toxicity paradigm defines DNA damage as the most critical biological effect inferred by IR [1,2]. Specifically, IR produces clustered DNA damage, particularly double-strand DNA breaks (DSBs). Signal transduction pathways and DNA repair systems are activated in response to IR to protect cells from injury. Discovery of radiosensitive human diseases has revealed two disease classes consistent with the distinct biological responses to IR: recognition of DSBs and repair of DSBs.

After tumor irradiation, the patients with one class of radiosensitive diseases developed severe dermatitis and deep tissue necrosis. This disease class includes ataxia-telangiectasia (AT) [3], the Nijmegen breakage syndrome (NBS) [4], ataxia-telangiectasia-like disorder (ATLD) [5] and Nijmegen breakage syndrome-like disorder (NBSLD) [6]. Genes responsible for these disorders have been identified as ATM for AT, NBS1 for NBS, MRE11A for ATLD and RAD50 for NBSLD [7]. Proteins encoded by these genes are all required for checkpoint response, a signal transduction pathway that recognizes DSBs [8].

Another class of radiosensitive diseases exhibits severe combined immunodeficiency (SCID), and the responsible genes are DNA-PKcs, Artemis and LIG4 (DNA ligase IV) [9]. Proteins encoded by these genes are involved in the repair of DSBs via a process called non-homologous end-joining (NHEJ) [10].

Identification of genes responsible for radiosensitive diseases allowed for development of radiosensitive mouse models. Mice deficient in Atm were created for targeting the checkpoint response [11]. However, inactivation of Mre11, Rad50, or Nbs1 led to early embryonic lethality, allowing only for models with conditional knock-out of these genes. In addition to MRN complex (Mre11, Rad50 and Nbs1) which recognizes DSB end and recruits ATM, other proteins are essential for IR-induced checkpoint and cell cycle arrest including H2AX and p53 [12]. Mice deficient in these proteins also demonstrate increased radiosensitivity [13]. SCID mouse models represent genes involved in IR-induced DSB repair through NHEJ [14].

Studies of mouse models of radiosensitive diseases demonstrated that immunodeficiency and elevated risk of leukemia/lymphoma associated with radiosensitivity is attributed to defects in DNA damage response and repair mechanisms acquired during development of the immune system. In the absence of checkpoint response, the risk of abnormal end joining of broken DNA is increased. Without NHEJ, the DSBs must be repaired by other less specific mechanisms to insure cell survival thus increasing probability of errors. Consequently, accumulation of cells with the abnormal DNA rearrangements may increase the risk of developing lymphoma/leukemia.

The most recent studies of molecular mechanisms underlying IR-induced cell death emphasize multiple pathways regulating cellular response to IR beyond DNA damage and repair. These pathways include membrane-dependent signaling pathways and by stander effect, a process of cellular response to irradiation of the neighboring cells rather than to direct IR exposure [15]. Targeting proteins regulating these pathways opens new avenues for development of new animal models of radiosensitivity. One recent example is a knockout of mitochondrial tumor suppressor Fus1 in mice. This model demonstrated novel radioprotective function for Fus1 which modulates radiosensitivity of normal tissues via regulation of anti-oxidant response pathways [16]. Interestingly, Fus1-deficient mice had increased frequency of spontaneous tumors and immunologic disorders [17,18], consistent with the mechanistic link of radiosensitivity to abnormal immune functions and increased risk of cancer.

References


*Corresponding author: Eugenia M Yazlovitskaya, Department of Medicine, Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Tel: 1-615-322-6679; Fax: 1-615-343-7156; E-mail: eugenia.yazlovitskaya@vanderbilt.edu

Received July 22, 2013; Accepted July 24, 2013; Published July 31, 2013


Copyright: © 2013 Yazlovitskaya EM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


